https://www.wacoca.com/news/2859659/ 新型コロナ変異株BA.3.2は強い免疫逃避能を示すが重症化の兆候はなく継続的な監視が必要 JAMA #BA32 #SARSCoV2 #オミクロン株 #変異株 #変異株影響 #感染症監視 #新型コロナウイルス

2/

Extract: “Dr. Bramante developed a program to study metformin as an outpatient treatment for acute SARS-CoV-2 because of its history as an anti-viral in the early 1900s and because of its known anti-inflammatory actions.”

#SarsCoV2 #PASC
#longcovid @longcovid @novid

Se on #pandemiaPerjantai ja uudet THL:n #SARS-Cov2 #jätevesi datat. Päivitetyt kaaviot, olkaa hyvät. - ainoastaan Rovaniemellä yli mittausrajan, muualla vähemmän - trendi jatkaa laskuaan ja virusmäärä on *lähes* olematon
Check out our latest publication on #SarsCoV2 Polymerase / ExoNuclease cooperativity and how it complexify treatment of coronavirus infections with nucleoside analogue antivirals . #pnas
https://www.pnas.org/doi/10.1073/pnas.2605725123
@afmblab.bsky.social
@PNASNews
@bioinformatics
@biophysics
@strucbio

RE: https://disabled.social/@tomkindlon/116721885357123392

Another thing kids with Long COVID aren't faking: how sensitive their eyes are to light.

This is not "in their heads", it shows up in measure after measure after measure.

https://www.nature.com/articles/s41598-026-54086-y

#COVID #COVID19 #SARSCov2 #LongCOVID #CovidIsNotOver

RE: https://disabled.social/@tomkindlon/116717085328668673

This study used a self-report for primary outcome, and found

Some secondary outcomes did have high posterior probabilities of efficacy, including 0.98 for symptom burden on day 120 and 0.96 for clinician diagnosis of long COVID on day 180.

So I think the real result from this study is "the study was underpowered" and not "metformin doesn't work for LC" because their results also cannot be distinguished from "metformin during acute COVID-19 reduces Long COVID rate by a quarter"

People who got Metformin:

  • were 24% less likely to self-report Long COVID at 180 days
  • were 22% less likely to be clinically diagnosed with Long COVID at 180 days

and consider their conclusion:

Metformin did not exceed the primary outcome threshold for declaring efficacy for reducing PASC. The posterior probability of efficacy for metformin was high for preventing a clinician diagnosis of long COVID and for symptom burden, consistent with prior clinical trial and observational data. No safety concerns occurred in this trial of metformin in low-risk adults. While a low event rate makes it challenging to evaluate therapeutics

https://dx.doi.org/10.1093/cid/ciag335

#COVID #COVID19 #SARSCoV2 #LongCOVID #Metformin #PASC

Prioritizing long COVID related single nucleotide polymorphisms by mining genome-wide association studies of COVID-19 susceptibility and hospitalization

https://www.frontiersin.org/journals/systems-biology/articles/10.3389/fsysb.2026.1797543/full

Screenshot from Science for ME weekly update

@longcovid
#LongCovid #PASC #PwLC #postcovid #postcovid19 #PostCovidSyndrome #LC #Covidlonghaulers #longhaulers #COVIDBrain #NeuroPASC
#Coronavirus
#COVID19 #COVID #COVID_19 #COVIDー19 #SARSCoV2 #auscovid19 #CovidIsNotOver

Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial

https://dx.doi.org/10.1093/cid/ciag335

"Metformin did not exceed the primary outcome threshold for declaring efficacy for reducing PASC."

@longcovid
#LongCovid #PwLC #PostCovidSyndrome #LC #PASC #postcovid
#CovidBrain
@[email protected] #COVIDー19 #COVID19 #COVID #COVID_19 #SARSCoV2 @novid #novid @[email protected] #CovidIsNotOver #auscovid19